Posted on 25th November 2014
Popular in the US, Avastin is used for patients with age-related macular degeneration (AMD). It has been on the market for years, gone through all the testing and has been proven to be as effective as Lucentis, the NHS approved drug for the same condition. The difference is cost. Lucentis typically costs around £700 per treatment, compared to Avastin which is about £70. Yet red tape seems to be halting its use.
It is currently unlicensed in the UK so should anything go wrong with its use, the practitioner may not be legally covered. However, in times of austerity and it is perhaps time for the NHS to move forward and license its use.
08th June 2017
Former managing director and founder of Cameron Optometry, Donald Cameron, attended the International Society of Contact Lens Specialists (ISCLS), along with Ian Cameron. Here Donald shares some of th...Read more
29th May 2017
For patients of the practice, you will know Carol Field, our dispensing practice manager. On Sunday Carol did something amazing. Carol completed the Edinburgh Marathon. The reason this is a particula...Read more